Zhang Y, Seidel M, Rabesahala de Meritens C, Beckmann A, Ahmed S, Hurtz M
Front Mol Biosci. 2025; 11():1505698.
PMID: 39777228
PMC: 11703740.
DOI: 10.3389/fmolb.2024.1505698.
Chen Y, Garcia-Castaneda M, Charalambous M, Rossi D, Sorrentino V, Van Petegem F
Nat Commun. 2024; 15(1):8630.
PMID: 39366997
PMC: 11452665.
DOI: 10.1038/s41467-024-52998-9.
Hadiatullah H, He Z, Yuchi Z
Front Pharmacol. 2022; 13:897494.
PMID: 35677449
PMC: 9168041.
DOI: 10.3389/fphar.2022.897494.
Engel M, Wormann Y, Kaestner H, Schuler C
Front Physiol. 2022; 13:691829.
PMID: 35399287
PMC: 8990320.
DOI: 10.3389/fphys.2022.691829.
Yin L, Zahradnikova Jr A, Rizzetto R, Boncompagni S, Rabesahala de Meritens C, Zhang Y
Circ Res. 2021; 129(3):e35-e52.
PMID: 34111951
PMC: 8320243.
DOI: 10.1161/CIRCRESAHA.121.319094.
Pathological conformations of disease mutant Ryanodine Receptors revealed by cryo-EM.
Woll K, Haji-Ghassemi O, Van Petegem F
Nat Commun. 2021; 12(1):807.
PMID: 33547325
PMC: 7864917.
DOI: 10.1038/s41467-021-21141-3.
A chloride channel blocker prevents the suppression by inorganic phosphate of the cytosolic calcium signals that control muscle contraction.
Ferreira J, Pequera G, Launikonis B, Rios E, Brum G
J Physiol. 2020; 599(1):157-170.
PMID: 32991741
PMC: 7775353.
DOI: 10.1113/JP279917.
Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
Zhang X, Wei H, Xia Y, Morad M
Heart Rhythm. 2020; 18(2):250-260.
PMID: 32931925
PMC: 7893824.
DOI: 10.1016/j.hrthm.2020.09.007.
Structure and Function of the Human Ryanodine Receptors and Their Association with Myopathies-Present State, Challenges, and Perspectives.
Bauerova-Hlinkova V, Hajduchova D, Bauer J
Molecules. 2020; 25(18).
PMID: 32899693
PMC: 7570887.
DOI: 10.3390/molecules25184040.
Regulatory mechanisms of ryanodine receptor/Ca release channel revealed by recent advancements in structural studies.
Ogawa H, Kurebayashi N, Yamazawa T, Murayama T
J Muscle Res Cell Motil. 2020; 42(2):291-304.
PMID: 32040690
PMC: 8332584.
DOI: 10.1007/s10974-020-09575-6.
Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family.
Tung M, Van Petegem F, Lauson S, Collier A, Hodgkinson K, Fernandez B
Mol Genet Genomic Med. 2020; 8(4):e1151.
PMID: 31994352
PMC: 7196448.
DOI: 10.1002/mgg3.1151.
Insights into channel modulation mechanism of RYR1 mutants using Ca2+ imaging and molecular dynamics.
Yamazawa T, Ogawa H, Murayama T, Yamaguchi M, Oyamada H, Suzuki J
J Gen Physiol. 2019; 152(1).
PMID: 31841587
PMC: 7034096.
DOI: 10.1085/jgp.201812235.
Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors.
Bennett J, Bernhardt M, McBride K, Reshmi S, Zmuda E, Kertesz N
Pediatr Cardiol. 2019; 40(8):1679-1687.
PMID: 31535183
DOI: 10.1007/s00246-019-02203-2.
Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2.
Alvarado F, Bos J, Yuchi Z, Valdivia C, Hernandez J, Zhao Y
JCI Insight. 2019; 5.
PMID: 30835254
PMC: 6483635.
DOI: 10.1172/jci.insight.126544.
Effective cascade screening through identification of a mutation in in a large family with a history of sudden death.
Bailey C, Blair E, Garratt C, Newman W
J Cardiol Cases. 2018; 13(1):9-13.
PMID: 30546600
PMC: 6281865.
DOI: 10.1016/j.jccase.2015.08.015.
Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry.
Roston T, Haji-Ghassemi O, LaPage M, Batra A, Bar-Cohen Y, Anderson C
PLoS One. 2018; 13(11):e0205925.
PMID: 30403697
PMC: 6221297.
DOI: 10.1371/journal.pone.0205925.
Promiscuous attraction of ligands within the ATP binding site of RyR2 promotes diverse gating behaviour.
Lindsay C, Sitsapesan M, Chan W, Venturi E, Welch W, Musgaard M
Sci Rep. 2018; 8(1):15011.
PMID: 30301919
PMC: 6177429.
DOI: 10.1038/s41598-018-33328-8.
CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression.
Liu Y, Wei J, Wong King Yuen S, Sun B, Tang Y, Wang R
PLoS One. 2017; 12(9):e0184177.
PMID: 28961276
PMC: 5621672.
DOI: 10.1371/journal.pone.0184177.
The N-Terminal Region of the Ryanodine Receptor Affects Channel Activation.
Faltinova A, Tomaskova N, Antalik M, Sevcik J, Zahradnikova A
Front Physiol. 2017; 8:443.
PMID: 28713282
PMC: 5492033.
DOI: 10.3389/fphys.2017.00443.
RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism.
Wang Y, Mesirca P, Marques-Sule E, Zahradnikova Jr A, Villejoubert O, DOcon P
JCI Insight. 2017; 2(8).
PMID: 28422759
PMC: 5396513.
DOI: 10.1172/jci.insight.91872.